
Dr. Martin Maron, director of the HCM Center at Lahey Hospital & Medical Center and national principal investigator of the ACACIA-HCM trial, joins Dr. Florian Rader of the HCM Center at Cedars-Sinai to discuss the trial’s findings on aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The conversation covers the long-standing treatment gap for the roughly half of non-obstructive patients who remain symptomatic on beta blockers or calcium channel blockers, the phase 3 trial design, and its co-primary endpoints of health status (KCCQ) and exercise capacity (peak VO2). Dr. Maron explains why the results are clinically meaningful and reviews secondary outcomes, including improvements in NT-proBNP and measures of diastolic function, along with consistent benefit across pre-specified subgroups such as patients with mid-cavitary obstruction. Additionally, the two discuss safety findings on ejection fraction reductions and heart failure events during dose titration, and how real-world monitoring and titration may look if aficamten is approved for this indication.
Flere episoder fra "In the Thick of It"



Gå ikke glip af nogen episoder af “In the Thick of It” - abonnér på podcasten med gratisapp GetPodcast.








